The global antiviral immunoglobulin market was valued at US$ 4.6 Billion in 2022 and is expected to reach US$ 10.9 Billion by 2033. By route of administration, the IV segment is projected to continue its growth momentum over the forecast period (2023 to 2033) with an anticipated compound annual growth rate (CAGR) of close to 7.4%. This growth is driven by factors such as the increasing prevalence of viral infections, expanding healthcare infrastructure, and advancements in IV administration techniques.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 4.6 Billion |
| Market Value 2023 | US$ 5.0 Billion |
| Market Value 2033 | US$ 10.9 Billion |
| CAGR 2023 to 2033 | 8.2% |
| Market Share of Top 5 Countries | 63.1% |
| Key Market Players | Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, BDI Pharma Inc., Bayers, Baxalta Incorporated, Kedrion SPA, AstraZeneca PLC., Omrix Biopharma, Sanofi, Cangene corporation. |
Immunoglobulins have traditionally assisted in opsonization, bacteriolysis stimulation, and toxin neutralization in bacterial infections. In viral infections, immunoglobulins prevent the infection of uninfected cells, support antibody-directed cell-mediated cytotoxicity by natural killer cells, and neutralize viruses either alone or in conjunction with complement. They offer a rapid, safe, and cost-effective approach to obtaining valuable information about an individual's health status.
Due to the global increase in immunosuppression caused by conditions such as AIDS, organ transplantation, tumors, autoimmune diseases, and the emergence of multidrug-resistant organisms, there is a renewed interest in the use of antibody preparations for preventing infections in high-risk populations. Substantial research has demonstrated that therapies aiming to promote or enhance the immune response may be feasible and beneficial for immunocompromised individuals.
Overall, immunoglobulins play a crucial role in various aspects of immune defense, providing targeted protection against pathogens and contributing to the well-being of individuals, particularly those with compromised immune systems.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market recorded a historic CAGR of 6.8% in the last 10 years from 2012 – 2022. The global antiviral immunoglobulins was around 4.7% of the overall US$ 97.14 Billion of the global antivirals market in 2022. The increasing prevalence of viral infections globally, including diseases such as HIV, hepatitis, and influenza, is a major driver for the antiviral immunoglobulin market. These infections impose a significant healthcare burden, necessitating a greater demand for antiviral treatments, including immunoglobulins. As viral infections continue to impact populations worldwide, the need for effective antiviral therapies such as immunoglobulins is on the rise, driving the growth of the market.
According to the data published by CDC in 2021, 36,136 people received an HIV diagnosis in the United States and dependent areas. The annual number of new diagnoses decreased by 7% from 2017 to 2021.
The use of immunoglobulins provides targeted and specific immune responses against viral pathogens, making them essential in combating viral infections and managing their associated complications.
Improvements in healthcare infrastructure, particularly in developing countries, have led to better access to antiviral immunoglobulin therapies. This expansion of healthcare facilities, along with increasing affordability and availability of antiviral immunoglobulins, contributes to market growth.
Viral outbreaks, such as influenza or emerging infectious diseases like COVID-19, lead to a surge in demand for antiviral immunoglobulin products. Synthetic biology offers a solution to the challenges associated with traditional antibody generation methods. A study conducted by Aaron Sato and published on February 5, 2020, highlighted how synthetic biology can address these issues, potentially leading to the development of novel medications through optimized antibodies.
Collaborative efforts in research, development, and commercialization can expand the market reach of antiviral immunoglobulin products and facilitate the exploration of new applications. Improved healthcare access in developing countries presents an opportunity for market expansion, as these regions often face a higher burden of viral infections and have a growing middle-class population with increased healthcare spending capacity.
The overall economic growth of a country or region significantly influences the demand for antiviral immunoglobulin products. During periods of economic growth, healthcare spending tends to increase, driving the demand for antiviral treatments.
Principal Consultant
Strict regulatory requirements, encompassing safety and efficacy evaluations, pose significant challenges to the development and commercialization of antiviral immunoglobulin products. The rigorous process of meeting these regulatory standards can be time-consuming and expensive, creating barriers to market entry and potentially restraining the demand for these products. Compliance with regulatory guidelines ensures the safety and effectiveness of immunoglobulin therapies but can also prolong the product development timeline and increase costs. These factors can impact the accessibility, affordability, and availability of antiviral immunoglobulin treatments, thus limiting their demand in the market.
In some cases, there may be alternative treatments available for viral infections, such as antiviral medications or vaccines. These alternatives may offer convenience, cost-effectiveness, or targeted therapeutic benefits, leading to reduced demand for antiviral immunoglobulin therapies.
In the year 2022, the U.S. holds a dominant share of 88.7% in the North American market, and it is expected to grow at a CAGR of 8.4% during the forecasted years. The U.S. is known for having one of the highest healthcare costs globally. However, this also facilitates widespread access and affordability for advanced medical therapies, including antiviral immunoglobulins. The increasing cost of healthcare drives the demand for innovative and effective treatments, thus expanding the market for antiviral immunoglobulin products.
The healthcare insurance system in the U.S. is complex, involving various commercial and governmental insurance companies. Fortunately, antiviral immunoglobulin therapy is often covered by these insurance policies, which improves patients' access to and affordability of these treatments. The coverage provided by insurance companies eases the financial burden on patients, ensuring they can benefit from antiviral immunoglobulin therapies.
In 2022, China emerged as the dominant player in the East Asia market, contributing around US$ 198.3 million. With the world's largest population, China faces a significant disease burden, leading to an increased demand for medical supplies, including antiviral immunoglobulins. This presents a lucrative market opportunity for manufacturers and sellers of these products, given the substantial patient pool in the country.
In May 2023, a prominent health expert in China predicted a potential surge of 65 million weekly COVID-19 cases in the country by June. This surge is fuelled by the XBB strain, a respiratory disease that has been spreading in China for nearly six months. With the virus still circulating and public immunity waning, there remains a possibility of the emergence of a new, more dangerous sub-variant. This ongoing situation further underscores the need for effective medical interventions such as antiviral immunoglobulins to address the challenges posed by the evolving viral landscape in China.
In 2022, Japan held a significant market share of around 57.3% in the East Asia market. Japan boasts highly skilled and well-trained healthcare professionals, including doctors, researchers, and technicians. Additionally, Japan has one of the highest proportions of elderly individuals globally. This demographic factor necessitates the use of antiviral immunoglobulins to treat or prevent viral infections in older populations.
The aging population in Japan has resulted in an increased demand for healthcare products, including antiviral immunoglobulins, to cater to their specific medical needs. The Japanese population benefits from a well-developed and established healthcare system that provides exceptional medical care. This advanced healthcare system creates an environment conducive to the production and utilization of antiviral immunoglobulin products, ensuring their accessibility and effectiveness in addressing the healthcare needs of the Japanese population.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The intravenous route of administration accounted for a significant market share of 52.3% in the global market in 2022. When administered intravenously, antiviral immunoglobulins can be rapidly and directly delivered into the bloodstream. This route of administration offers enhanced bioavailability and a prompt response against infections compared to other methods such as oral or subcutaneous administration.
By delivering antiviral immunoglobulins intravenously, the effective targeting of the medication to the desired location is ensured, leading to improved efficacy and treatment outcomes. Intravenous administration allows healthcare professionals to precisely control the delivery of antiviral immunoglobulins to the patient. They can accurately measure and adjust the dosage based on the individual patient's needs. This dose consistency contributes to optimal therapeutic results while minimizing the risk of under or overdosing.
Hospital pharmacies play a significant role in the antiviral immunoglobulin market, representing 42.5% of end users in 2022 and exhibiting a CAGR of 9.8% over the forecast period. Hospitals are often the primary healthcare facility patients turn to when they contract a viral illness. In the hospital setting, intravenous administration of antiviral immunoglobulin is commonly employed for the treatment of patients with severe viral infections. This ensures close monitoring by medical staff and allows for prompt adjustments to the treatment plan based on the patient's response. Hospitals possess the necessary infrastructure and expertise to administer these drugs intravenously, ensuring the safe and effective delivery of antiviral immunoglobulins to patients.
The population may become less in need of antiviral treatments due to population immunity brought on by high vaccination rates and prior diseases.
With technological advances in the pharmaceutical sector, Antiviral Immunoglobulin will be useful in countering viral infections.
Similarly, recent developments related to the company’s active in the antiviral immunoglobulin market have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | US$ Million for Value, Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East, and Africa (MEA) |
| Key Countries Covered | U.S., Canada, Brazil, Mexico, Argentina, Germany, Italy, France, U.K., Spain, BENELUX, Russia, India, Thailand, China, Indonesia, Malaysia, Japan, South Korea, Australia, New Zealand, GCC countries, Northern Africa and South Africa. |
| Key Market Segments Covered | Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Report Coverage |
|
| Pricing | Available upon Request |
The market is valued at US$ 5 billion in 2023.
From 2012 to 2022, the market registered a CAGR of 6.8%.
The market shall reach US$ 10.9 billion in 2033.
The market’s CAGR from 2023 to 2033 will be 7.4%.
In 2022, the U.S. held a share of 88.7% of the North American market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value-Added Insights
4.1. Product Adoption and Usage Analysis-By Region
4.2. Product Vs Application Matrix, By Brands
4.3. Regulatory Landscape, By Country
4.4. Reimbursement Scenario, By Country
4.5. Porter’s Analysis
4.6. PESTLE Analysis
4.7. Value Chain Analysis
4.8. Patient Unmet Needs for Treatment
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Life Science Market Outlook
5.1.3. Global Immunoglobulin Market Outlook (Parent Market Outlook)
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Prevalence of Immunodeficiency Diseases
5.2.2. Technological Advancements in Manufacturing
5.2.3. The emergence of new and re-emerging infectious diseases, such as Ebola, Zika, and COVID-19
5.2.4. Improvements in healthcare infrastructure in developing countries
5.2.5. Government Initiatives and Funding
5.2.6. Increased awareness about viral infections and their potential complications
5.2.7. The rising incidence of viral infections worldwide
5.2.8. Cost of Treatment
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand Volume (Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Volume (Unit) Analysis, 2012 to 2022
6.2. Current and Future Market Volume (Units) Analysis and Forecast Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Market – Pricing Analysis
7.1. Regional Pricing Analysis By Antiviral Immunoglobulin
7.2. Global Average Pricing Analysis Benchmark
7.3. Pricing Assumptions
8. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033
8.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022
8.2. Current and Future Market Size (US$ Million) Analysis and Forecast Projections, 2023 to 2033
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2012 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
9.3.1. Intravenous
9.3.2. Subcutaneous
9.3.3. Intramuscular Injections
9.4. Market Attractiveness Analysis By Route of Administration
10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2012 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Drug Stores
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By Region, 2012 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. South Asia
11.3.5. East Asia
11.3.6. Oceania
11.3.7. Middle East and Africa
11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Route of Administration
12.3.3. By Distribution Channel
12.4. Market Attractiveness Analysis By Region
12.4.1. By Country
12.4.2. By Route of Administration
12.4.3. By Distribution Channel
12.5. Market trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. U.S. Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Route of Administration
12.8.1.2.2. By Distribution Channel
12.8.2. Canada Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Route of Administration
12.8.2.2.2. By Distribution Channel
13. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Route of Administration
13.3.3. By Distribution Channel
13.4. Market Attractiveness Analysis By Region
13.4.1. By Country
13.4.2. By Route of Administration
13.4.3. By Distribution Channel
13.5. Market trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Brazil Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Route of Administration
13.8.1.2.2. By Distribution Channel
13.8.2. Mexico Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Route of Administration
13.8.2.2.2. By Distribution Channel
13.8.3. Argentina Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Route of Administration
13.8.3.2.2. By Distribution Channel
14. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. France
14.3.1.3. Spain
14.3.1.4. Italy
14.3.1.5. Russia
14.3.1.6. BENELUX
14.3.1.7. United Kingdom
14.3.1.8. Rest of Europe
14.3.2. By Route of Administration
14.3.3. By Distribution Channel
14.4. Market Attractiveness Analysis By Region
14.4.1. By Country
14.4.2. By Route of Administration
14.4.3. By Distribution Channel
14.5. Market trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Germany Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Route of Administration
14.8.1.2.2. By Distribution Channel
14.8.2. France Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Route of Administration
14.8.2.2.2. By Distribution Channel
14.8.3. Spain Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Route of Administration
14.8.3.2.2. By Distribution Channel
14.8.4. Russia Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Route of Administration
14.8.4.2.2. By Distribution Channel
14.8.5. Italy Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Route of Administration
14.8.5.2.2. By Distribution Channel
14.8.6. BENELUX Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Route of Administration
14.8.6.2.2. By Distribution Channel
14.8.7. United Kingdom Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Route of Administration
14.8.7.2.2. By Distribution Channel
15. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Indonesia
15.3.1.3. Thailand
15.3.1.4. Malaysia
15.3.1.5. Rest of South Africa
15.3.2. By Route of Administration
15.3.3. By Distribution Channel
15.4. Market Attractiveness Analysis By Region
15.4.1. By Country
15.4.2. By Route of Administration
15.4.3. By Distribution Channel
15.5. Market trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. India Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Route of Administration
15.8.1.2.2. By Distribution Channel
15.8.2. Indonesia Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Route of Administration
15.8.2.2.2. By Distribution Channel
15.8.3. Thailand Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Route of Administration
15.8.3.2.2. By Distribution Channel
15.8.4. Malaysia Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Route of Administration
15.8.4.2.2. By Distribution Channel
16. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
16.1. Introduction / Key Findings
16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Route of Administration
16.3.3. By Distribution Channel
16.4. Market Attractiveness Analysis By Region
16.4.1. By Country
16.4.2. By Route of Administration
16.4.3. By Distribution Channel
16.5. Market trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Route of Administration
16.8.1.2.2. By Distribution Channel
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Route of Administration
16.8.2.2.2. By Distribution Channel
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Route of Administration
16.8.3.2.2. By Distribution Channel
17. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033
17.1. Introduction / Key Findings
17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Route of Administration
17.3.3. By Distribution Channel
17.4. Market Attractiveness Analysis By Region
17.4.1. By Country
17.4.2. By Route of Administration
17.4.3. By Distribution Channel
17.5. Market trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Australia Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Route of Administration
17.8.1.2.2. By Distribution Channel
17.8.2. New Zealand Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Route of Administration
17.8.2.2.2. By Distribution Channel
18. Middle East and Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033
18.1. Introduction / Key Findings
18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Türkiye
18.3.1.3. South Africa
18.3.1.4. Northern Africa
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Route of Administration
18.3.3. By Distribution Channel
18.4. Market Attractiveness Analysis By Region
18.4.1. By Country
18.4.2. By Route of Administration
18.4.3. By Distribution Channel
18.5. Market trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. GCC Countries Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Route of Administration
18.8.1.2.2. By Distribution Channel
18.8.2. Türkiye Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Route of Administration
18.8.2.2.2. By Distribution Channel
18.8.3. South Africa Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Route of Administration
18.8.3.2.2. By Distribution Channel
18.8.4. Northern Africa Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Route of Administration
18.8.4.2.2. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players (%)
19.3. Market Presence Analysis
19.3.1. Regional Footprint of Players
19.3.2. Route of Administration Footprint of Players
19.3.3. Channel Footprint of Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Key Development Analysis
20.3. Competition Benchmarking
20.4. Competition Deep Dive
20.4.1. Biotest AG
20.4.1.1. Overview
20.4.1.2. Product Portfolio
20.4.1.3. Key Financials
20.4.1.4. Sales Footprint
20.4.1.5. Strategy Overview
20.4.1.6. Marketing Strategies
20.4.1.7. Channel Strategies
20.4.2. Baxter International Inc.
20.4.2.1. Overview
20.4.2.2. Product Portfolio
20.4.2.3. Key Financials
20.4.2.4. Sales Footprint
20.4.2.5. Strategy Overview
20.4.2.6. Marketing Strategies
20.4.2.7. Channel Strategies
20.4.3. Octapharma AG
20.4.3.1. Overview
20.4.3.2. Product Portfolio
20.4.3.3. Key Financials
20.4.3.4. Sales Footprint
20.4.3.5. Strategy Overview
20.4.3.6. Marketing Strategies
20.4.3.7. Channel Strategies
20.4.4. LFB Biotechnologies
20.4.4.1. Overview
20.4.4.2. Product Portfolio
20.4.4.3. Key Financials
20.4.4.4. Sales Footprint
20.4.4.5. Strategy Overview
20.4.4.6. Marketing Strategies
20.4.4.7. Channel Strategies
20.4.5. Grifols SA
20.4.5.1. Overview
20.4.5.2. Product Portfolio
20.4.5.3. Key Financials
20.4.5.4. Sales Footprint
20.4.5.5. Strategy Overview
20.4.5.6. Marketing Strategies
20.4.5.7. Channel Strategies
20.4.6. CSL Behring
20.4.6.1. Overview
20.4.6.2. Product Portfolio
20.4.6.3. Key Financials
20.4.6.4. Sales Footprint
20.4.6.5. Strategy Overview
20.4.6.6. Marketing Strategies
20.4.6.7. Channel Strategies
20.4.7. China Biologics Route of Administrations Inc.
20.4.7.1. Overview
20.4.7.2. Product Portfolio
20.4.7.3. Key Financials
20.4.7.4. Sales Footprint
20.4.7.5. Strategy Overview
20.4.7.6. Marketing Strategies
20.4.7.7. Channel Strategies
20.4.8. Kedrion Biopharma
20.4.8.1. Overview
20.4.8.2. Product Portfolio
20.4.8.3. Key Financials
20.4.8.4. Sales Footprint
20.4.8.5. Strategy Overview
20.4.8.6. Marketing Strategies
20.4.8.7. Channel Strategies
20.4.9. BDI Pharma Inc.
20.4.9.1. Overview
20.4.9.2. Product Portfolio
20.4.9.3. Key Financials
20.4.9.4. Sales Footprint
20.4.9.5. Strategy Overview
20.4.9.6. Marketing Strategies
20.4.9.7. Channel Strategies
20.4.10. Bayers
20.4.10.1. Overview
20.4.10.2. Product Portfolio
20.4.10.3. Key Financials
20.4.10.4. Sales Footprint
20.4.10.5. Strategy Overview
20.4.10.6. Marketing Strategies
20.4.10.7. Channel Strategies
20.4.11. Biotest AG
20.4.11.1. Overview
20.4.11.2. Product Portfolio
20.4.11.3. Key Financials
20.4.11.4. Sales Footprint
20.4.11.5. Strategy Overview
20.4.11.6. Marketing Strategies
20.4.11.7. Channel Strategies
20.4.12. Baxalta Incorporated
20.4.12.1. Overview
20.4.12.2. Product Portfolio
20.4.12.3. Key Financials
20.4.12.4. Sales Footprint
20.4.12.5. Strategy Overview
20.4.12.6. Marketing Strategies
20.4.12.7. Channel Strategies
20.4.13. Kedrion SPA
20.4.13.1. Overview
20.4.13.2. Product Portfolio
20.4.13.3. Key Financials
20.4.13.4. Sales Footprint
20.4.13.5. Strategy Overview
20.4.13.6. Marketing Strategies
20.4.13.7. Channel Strategies
20.4.14. Astrazeneca PLC.
20.4.14.1. Overview
20.4.14.2. Product Portfolio
20.4.14.3. Key Financials
20.4.14.4. Sales Footprint
20.4.14.5. Strategy Overview
20.4.14.6. Marketing Strategies
20.4.14.7. Channel Strategies
20.4.15. Omrix Biopharma.
20.4.15.1. Overview
20.4.15.2. Product Portfolio
20.4.15.3. Key Financials
20.4.15.4. Sales Footprint
20.4.15.5. Strategy Overview
20.4.15.6. Marketing Strategies
20.4.15.7. Channel Strategies
20.4.16. Sanofi
20.4.16.1. Overview
20.4.16.2. Product Portfolio
20.4.16.3. Key Financials
20.4.16.4. Sales Footprint
20.4.16.5. Strategy Overview
20.4.16.6. Marketing Strategies
20.4.16.7. Channel Strategies
20.4.17. Cangene corporation
20.4.17.1. Overview
20.4.17.2. Product Portfolio
20.4.17.3. Key Financials
20.4.17.4. Sales Footprint
20.4.17.5. Strategy Overview
20.4.17.6. Marketing Strategies
20.4.17.7. Channel Strategies
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Antiviral Immunoglobulin Market
